← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
asunaprevir
J05AP06
Forms & Strengths
- 100 mg and 200 mg capsules or tablets
Adult Dosing
- 100 mg orally twice daily for 24 weeks in combination with daclatasvir for genotype 1b
- 200 mg orally once daily for 24 weeks in combination with daclatasvir for genotype 1b
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Use not recommended in patients under 18 years
Indications
- Treatment of chronic hepatitis C virus genotype 1b infection in adults
- Used in combination with daclatasvir for treatment of genotype 1b
Mechanism of Action
- Inhibits NS3 protease of hepatitis C virus
- Blocks viral replication by preventing polyprotein processing
Contraindications
- Pregnancy and lactation due to potential harm
- Concomitant use with strong CYP3A4 inducers or inhibitors
- Hypersensitivity to asunaprevir
Adverse Reactions
- Common: headache, diarrhea, fatigue, and nausea
- Severe: anemia, neutropenia, thrombocytopenia, and liver enzyme elevation
Drug Interactions
- Avoid concomitant use with carbamazepine, phenytoin, and rifampin due to decreased efficacy
- Use caution with clarithromycin, erythromycin, and ketoconazole due to increased exposure and potential toxicity
Curated Content: Needs Vetting Before Put to Clinical Use